- Qure.ai secures $65 million in Series D funding to expand into the US, invest in AI models, and acquire complementary med-tech firms.
- The AI-led healthtech company's solutions are deployed in over 90 countries across 3000+ sites, with 18 FDA-cleared indications and Class IIb certification per EU MDR regulations.
Qure.ai, an AI-led healthtech company, has recently announced the completion of a $65 million Series D funding round. According to the company, the funds will support its expansion into the US and other regions, boost investment in core AI models, and facilitate acquisitions of complementary med-tech firms.
@qure_ai has secured $65 million in a Series D funding round led by @lightspeedvp and @360ONEAsset, with participation from Merck Global Health Innovation Fund, @KaeCapital, and our existing investors, including @novoholdings, @healthquad, and TEAMFund.
— Qure.ai (@qure_ai) September 25, 2024
This investment marks a…
The round was led by new strategic and financial investors, including Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund and Kae Capital. Existing backers such as Novo Holdings, Health Quad, and TeamFund also contributed to the round.
“Qure.ai has become a trusted medical imaging AI partner to hospitals and healthcare organisations around the world. Our work is helping to unlock clinical efficiencies and drive up the standard of care delivered to patients in the focus areas of TB, Lung Cancer and Stroke”, said Prashant Warier, Co-founder and CEO of Qure.ai.
Warier also highlighted that AI addresses healthcare challenges such as imaging reporting backlogs, low screening rates, and workforce shortages, not only in Western countries like the US and Europe but also in developing nations.
He mentioned that the company collaborates with half of the top 20 Pharma and MedTech companies, including AstraZeneca, Medtronic, and J&J, to advance early diagnosis and timely treatment of diseases. Also, he added that the Series D funding marks an exciting milestone in their mission to reach a billion patients with their solutions.
Founded in 2016, Qure.ai is on a mission to make healthcare more accessible and equitable globally. This has driven its AI solution development, positioning the company as the world’s most deployed healthcare AI. Qure.ai solutions are deployed in over 90 countries across 3000+ sites, powering the efficient identification and management of critical diseases.
The company has 18 FDA-cleared indications, and its products are Class IIb certified per EU MDR* regulations. Qure.ai is headquartered in Mumbai, with regional offices in New York, London, and Dubai.
Edited by Harshajit Sarmah
ALSO READ:
Tanay Chopra
